期刊文献+

CD117、C-erbB-2及表皮生长因子受体在原发性肝癌组织中的表达及其临床意义 被引量:8

Expression and clinical significance of CD117,C-erbB-2 and EGFR in primary hepatocellular carcinoma
原文传递
导出
摘要 目的 检测原发性肝癌组织中CD117、C-erbB-2及表皮生长因子受体(EGFR)表达,探讨其在肝癌诊断和治疗中的意义.方法 经病理确诊的127例原发性肝癌患者,采用免疫组织化学法检测肿瘤组织中CD117、C-erbB-2及EGFR表达,分析其与肿瘤数目、直径、血管侵犯、组织分化及甲胎蛋白(AFP)水平关系.结果 CD117、C-erbB-2及EGFR阳性表达率分别为32.3%(41/127)、22.8%(29/127)和27.6%(35/127),CD117表达与肿瘤数目、直径和血管侵犯明显相关;C-erbB-2表达与肿瘤直径、血管侵犯和肿瘤分化明显相关;EGFR表达与肿瘤数目、AFP水平和肿瘤分化明显相关.结论 肝癌组织表达CD117、C-erbB-2及EGFR与肿瘤形态和生物学特性有关,对肝癌预后判断和靶向治疗具有一定指导意义. Objective To investigate the expression of CD117,C-erbB-2 and epidermal growth factor receptor (EGFR) in primary hepatocellular carcinoma (HCC) tissue and their diagnostic and therapeutic significance.Methods The expression of CD117,C-erbB-2 and EGFR in 127 cases of HCC tissues was detected by using immunohistochemstry.The relationship of their positive staining rate with tumor number,size,vascular invasion,tissue differentiation and alpha fetoprotein (AFP) level was analyzed.Results The positive staining rate of CD117,C-erbB-2 and EGFR in HCC tissue was 32.3% (41/127),22.8% (29/127) and 27.6% ( 35/127),respectively.The expression of CD117 was significantly associated with patients' tumor number,size and vascular invasion,while C-erbB-2 with tumor size,vascular invasion and tissue differentiation,and EGFR with tumor size,AFP level and tissue differentiation.Conclusion The expression of CD117,C-erbB-2 and EGFR in HCC tissue had some relationship with tumor morphological and biological characteristics,which may help predict the prognosis of HCC and prescribe target therapy in future.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2010年第12期1815-1817,共3页 Chinese Journal of Experimental Surgery
关键词 肝细胞 CD117 C-ERBB-2 EGFR Carcinoma,hepatocellular CD117 C-erbB-2 EGFR
  • 相关文献

参考文献11

  • 1杨帆,周足力,姜冠潮,黄宇清,彭洁,王俊.肺癌中表皮生长因子受体过表达与女性、非吸烟、腺癌和基因突变的关系[J].中华实验外科杂志,2007,24(8):973-974. 被引量:12
  • 2王磊,蔡永东,王汉晋,卞建民.乳腺癌细胞中表皮生长因子对雌激素受体表达的影响及机制[J].中华实验外科杂志,2007,24(6):742-744. 被引量:3
  • 3Lux ML,Rubin BP,Biase TL,et al.KIT extraceliular and kinase domain mutations in gastrointestinal stromal tumors.Am J Pathol,2000,156:791-795.
  • 4Jeng YM,Lin CY,Hsu HC.Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma.Cancer Lett,2000,154:107-111.
  • 5Verweij J,Judson I,Van Oosterom A.STI571:a magic bullet? Eur J Cancer,2001,37:1816-1819.
  • 6Mamounas EP.Present state and future prospects:a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer.Clin Breast Cancer,2001,2:20-30.
  • 7Llovet JM,Bru C,Bruix J.Prognosis of hepatocellular carcinoma:the BCLC staging classification.Semin Liver Dis,1999,19:329-338.
  • 8Chung CY,Yeh KT,Hsu NC,et al.Expression of c-kit protooncogene in human hepatocellular carcinoma.Cancer Lett,2005,217:231-236.
  • 9Philip PA,Mahoney MR,Allmer C,et al.Phase Ⅱ study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.J Clin Oncol,2005,23:6657-6663.
  • 10Kara B,Doran F,Kara IO,et al.Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis,cirrhosis and hepatocellular carcinoma:has it a diagnostic role? Int J Clin Pract,2008,62:1206-1211.

二级参考文献10

  • 1王汉晋,武正炎,范萍,卞建民.核转录因子κB激活对雌激素受体阴性乳腺癌细胞增殖的影响[J].中华外科杂志,2005,43(15):1014-1016. 被引量:1
  • 2高尚志.我国心胸外科实验研究目前的热点和问题[J].中华实验外科杂志,2006,23(9):1031-1032. 被引量:3
  • 3Iwase H, Omoto Y, Iwata H, et al. Estrogen receptor alpha mRNA variant lacking exon 5 is co-expressed with the wild-type in endometrial adenocarcinoma. Eur J Obstet Gynecol Repred Biol,2002, 102: 92295.
  • 4Lei Z ,Ping G, Sulian S, et al. Laeking exon5 of varlant estrogen receptor in human breast cancer. Chin J Cancer Res, 1998,10 : 130-133.
  • 5Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat ,2002,71:67-75.
  • 6Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curt Opin Oncol,2005,17 : 118-122.
  • 7Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst ,2005,97:643-655.
  • 8Paez JG ,Janne PA ,Lee JC ,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science,2004,304: 1497-1500.
  • 9Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer,2006, 118:257-262.
  • 10Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med ,2005,2 : 1085-1087.

共引文献13

同被引文献87

引证文献8

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部